144 related articles for article (PubMed ID: 37155986)
21. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
Sun L; Brentnall A; Patel S; Buist DSM; Bowles EJA; Evans DGR; Eccles D; Hopper J; Li S; Southey M; Duffy S; Cuzick J; Dos Santos Silva I; Miners A; Sadique Z; Yang L; Legood R; Manchanda R
JAMA Oncol; 2019 Dec; 5(12):1718-1730. PubMed ID: 31580391
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of the NHS breast screening programme: life table model.
Pharoah PD; Sewell B; Fitzsimmons D; Bennett HS; Pashayan N
BMJ; 2013 May; 346():f2618. PubMed ID: 23661112
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Kazi DS; Penko J; Coxson PG; Guzman D; Wei PC; Bibbins-Domingo K
Ann Intern Med; 2019 Feb; 170(4):221-229. PubMed ID: 30597485
[TBL] [Abstract][Full Text] [Related]
24. A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States.
Vanness DJ; Lomas J; Ahn H
Ann Intern Med; 2021 Jan; 174(1):25-32. PubMed ID: 33136426
[TBL] [Abstract][Full Text] [Related]
25. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
[TBL] [Abstract][Full Text] [Related]
26. Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.
Cusick MM; Tisdale RL; Chertow GM; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2023 Jun; 176(6):788-797. PubMed ID: 37216661
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract][Full Text] [Related]
29. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.
JAMA; 1998 Nov; 280(20):1757-63. PubMed ID: 9842951
[TBL] [Abstract][Full Text] [Related]
30. A review of the cost-effectiveness of genetic testing for germline variants in familial cancer.
Teppala S; Hodgkinson B; Hayes S; Scuffham P; Tuffaha H
J Med Econ; 2023; 26(1):19-33. PubMed ID: 36426964
[TBL] [Abstract][Full Text] [Related]
31. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
32. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.
Juusola JL; Brandeau ML; Owens DK; Bendavid E
Ann Intern Med; 2012 Apr; 156(8):541-50. PubMed ID: 22508731
[TBL] [Abstract][Full Text] [Related]
34. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC
Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
[TBL] [Abstract][Full Text] [Related]
35. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
36. Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States : A Cost-Effectiveness Analysis.
Basu A; Winn AN; Johnson KM; Jiao B; Devine B; Hankins JS; Arnold SD; Bender MA; Ramsey SD
Ann Intern Med; 2024 Feb; 177(2):155-164. PubMed ID: 38252942
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
Hutton DW; Tan D; So SK; Brandeau ML
Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
[TBL] [Abstract][Full Text] [Related]
38. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
[TBL] [Abstract][Full Text] [Related]
39. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
Blake GJ; Ridker PM; Kuntz KM
Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]